Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Glucocorticoids and endothelial cell barrier function

Ellaine Salvador, Sergey Shityakov, Carola Förster

Cell and Tissue Research · 2013 · Review

doi:10.1007/s00441-013-1762-z

Abstract

Glucocorticoids (GCs) are steroid hormones that have inflammatory and immunosuppressive effects on a wide variety of cells. They are used as therapy for inflammatory disease and as a common agent against edema. The blood brain barrier (BBB), comprising microvascular endothelial cells, serves as a permeability screen between the blood and the brain. As such, it maintains homeostasis of the central nervous system (CNS). In many CNS disorders, BBB integrity is compromised. GC treatment has been demonstrated to improve the tightness of the BBB. The responses and effects of GCs are mediated by the ubiquitous GC receptor (GR). Ligand-bound GR recognizes and binds to the GC response element located within the promoter region of target genes. Transactivation of certain target genes leads to improved barrier properties of endothelial cells. In this review, we deal with the role of GCs in endothelial cell barrier function. First, we describe the mechanisms of GC action at the molecular level. Next, we discuss the regulation of the BBB by GCs, with emphasis on genes targeted by GCs such as occludin, claudins and VE-cadherin. Finally, we present currently available GC therapeutic strategies and their limitations.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Glucocorticoids (GCs) belong to a class of steroid hormones that bind to GC receptors (GRs), which, once activated as a complex, upregulate the expression of anti-inflammatory proteins in the nucleus and repress the expression of proinflammatory proteins in the cytosol (Rhen and Cidlowski ). GCs are the first-choice therapy for inflammatory disease and a common anti-edematous agent. Administration of GCs is employed as a novel treatment strategy for several central nervous system (CNS) diseases such as brain tumors, brain edema and multiple sclerosis (MS).

The neurovascular unit of the CNS is made up of microvascular endothelial cells that seal the paracellular spaces between the blood and brain and, thus, are often referred to as the blood brain barrier (BBB), together with circulating blood components, pericytes, astrocytes and neurons (Neuwelt et al. ). In many disorders of the CNS, the integrity of the BBB is compromised. Since GCs are found to improve barrier properties, they are often used for the therapy of CNS disorders that involve the BBB. GC treatment has demonstrated a tightening of the BBB in the murine microvascular brain endothelial cells, cEND (Förster et al., ).

Mechanisms of GC action at the molecular level

GCs act on a wide variety of cell types leading to many different physiological and pathological responses and systemic effects. These responses and effects are mostly attributable to the ubiquitous nature of the GR. The action of GCs begins when the GC crosses the cell membrane and binds to a GR (Fig. 1). GRs are located in the cytoplasm and belong to the thyroid/retinoic acid receptor superfamily, which is composed of ligand-dependent transcription factors (Evans; Tsai and O’Malley ). Within the cytoplasm, GRs are maintained in an inactive state by being bound to heat shock proteins (hsps) to prevent them from moving into the nucleus (Wikstrom et al.; Picard et al.; Dao-Phan et al. ). Once the GC binds to a GR, the hsps dissociate and the GC-GR complex then translocates into the nucleus in which it dimerizes with a second GC-GR complex (Dittmar et al.; Hawle et al. ).

The zinc-finger domains of the GR can bind to specific DNA sequences, i.e., GC-responsive elements (GREs), in the 5′ promoter region. The GR can then activate transcription in a process termed GR transactivation (Beato; Schaaf and Cidlowski; Harke et al. ). However, if the region contains a negative GRE, transcription is repressed (Sakai et al.; Drouin et al.; Nakai et al.; Subramaniam et al. ).

The inflammatory and immunosuppressive effects of GCs rely on several molecular mechanisms that include (1) direct effects on gene expression by the binding of GRs to GREs; (2) indirect effects on gene expression by the interaction of GRs with other transcription factors; (3) GR-mediated effects on second messenger cascades, i.e., the P13K-Akt-eNOS pathway (Rhen and Cidlowski ).

Glucocorticoid receptor

GRs mediate the biological effects of GCs (Beato ). They are a type II steroid receptor and transcription factor and alter the expression of target genes involved in multiple cellular processes such as immune function, inflammation and cell death (Schaaf and Cidlowski ). As a type II receptor, GR is expressed in almost all tissues and cells. It has a binding affinity for cortisol of approximately 30 nM, which is within the physiological range of serum cortisol values (Umland et al. ). GR is expressed in two isoforms, namely, GRα and GRβ, which share identical N-termini and are distinguished only by their unique C-terminal ligand-binding domain (Lewis-Tuffin and Cidlowski ). GRα binds cortisol, DNA and other transcription factors, thereby modifying the transcriptional activity of target genes (Lu and Cidlowski ). On the other hand, GRβ does not bind any ligands and fails to activate transcription, although it forms homodimers that bind DNA. Relative levels of these two GR isoforms in a cell influence the sensitivity of the cell to GC. Higher levels of GRβ lead to GC resistance (Pujols et al. ).

Blood brain barrier

The BBB is a diffusion barrier essential for the normal functioning of the CNS (Ballabh et al. ). It is composed of highly specialized endothelial cells, which, together with circulating blood components, pericytes, astrocytes, microglia, neurons and basement membrane form a neurovascular unit (Neuwelt et al. ). The capillary endothelial cells that make up the BBB are formed by tight junctions (TJs) that seal paracellular spaces between the endothelial cells thereby restricting paracellular permeability (Wolburg and Lippoldt; Förster ). The integral membrane proteins claudin, occludin and junction adhesion molecules make up the TJs, alongside a number of cytoplasmic accessory proteins including zonula occludens (ZO)-1, ZO-2, ZO-3 and cingulin (Ballabh et al. ). Junctional protein disintegration plays a major role in BBB breakdown during MS, meningitis, or brain neoplasm (Förster et al. ).

Regulation of BBB by GCs

Many factors regulate the BBB. Changes in the expression of junctional proteins in the endothelial cells through metabolic or cellular mediators play a role in this regulation leading to dynamic changes in BBB properties (Madra et al.; Madara; Schneeberger and Lynch; Citi; Leach et al.; Schweingruber et al. ). However, GCs are also important regulators of BBB properties together with other factors such as growth factors or calcium. Treatment of tumor-induced brain edema by GC reduces microvessel permeability. Several studies have demonstrated the molecular mechanisms behind this. For instance, treatment of epithelial cells with dexamethasone, a synthetic GC, influences the differentiation of TJ proteins (Buse et al. ). It increases transendothelial electrical resistance (TER) and ZO-1 expression (Singer et al. ). In addition, dexamethasone has also been found to influence TJ expression leading to a reduction of permeability in rat (Romero et al.; Calabria et al. ), murine (Förster et al.; Weidenfeller et al. ), porcine (Hoheisel et al.; Lohmann et al. ) and human (Weksler et al.; Förster ) endothelial cells. In the advent of a neuroinflammatory response, cell adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) become upregulated on endothelial cells facilitating lymphocyte extravasation across the BBB (Engelhardt ). GCs inhibit BBB disruption thereby reducing leukocyte infiltration into the CNS (Paul and Bolton ).

Occludin

The TJ protein occludin was the first integral protein to be identified, initially in the chicken (Furuse et al. ) and then in mammals (Anko-Akatsuka et al. ). It is composed of four transmembrane domains, two extracellular loops of similar size, three cytoplasmic domains, a short cytoplasmic N-terminus and a long C-terminus (Gonzalez-Mariscal et al. ). Although occludin localizes at the TJs, it cannot form TJ strands by itself (Furuse et al. ). In addition, the formation of an effective diffusion barrier and epithelial cell polarization are not prevented by the disruption of both occludin alleles in embryonic stem cells (Saitou et al. ). Moreover, occludin knock-out mice display well-developed TJs (Saitou et al. ).

Nonetheless, several lines of evidence show that occludin plays an important role at TJs. It contributes to the electrical barrier function of TJs and possibly to the formation of aqueous pores within TJ strands (McCarthy et al. ). Moreover, the N-terminal half of occludin has demonstrated its important role for TJ assembly and barrier function maintenance (Bamforth et al. ). Overexpression of occludin increases TER in mammalian epithelial cells (Balda et al. ). Originally hydrocortisone (HC) was reported to reinforce blood–brain properties in a serum-free cell culture system of cultured porcine cerebral capillary endothelial cells (Hoheisel et al. ). Next, GCs were shown to induce a more differentiated BBB phenotype through the modification of TJ structure in cultured rat brain endothelial cells (Romero et al. ). Then, the tightening effects of GC treatment was demonstrated in the murine cerebrovascular endothelial cell line cEND (Förster et al., ) and in human hDMEC/D3 cells (Förster ). Study of GC effects on the improvement of BBB properties in a murine in vitro system was, for the first time, able to identify occludin as a direct target for GC (Förster et al. ). GCs were shown to induce occludin expression (Fig. 2); this was dependent on the GR. A GC response element (GRE) was identified as a GR-binding site within the occludin promoter. This indicated that transactivation of occludin occurred through the GRE (Harke et al. ). Moreover, GC treatment antagonized the effects of tumor necrosis factor-α (TNF-α) on occludin expression in endothelial cell lines (Silwedel and Förster ).

Claudins

Despite disruption of both alleles of the occludin gene in embryonic stem (ES) cells, well-developed TJs were found between adjacent epithelial cells. This led to the conclusion that occludin was not necessarily required for TJ formation itself and indicated that other unidentified TJ integral membrane protein(s) could form strand structures without occludin (Saitou et al. ). Concomitantly, peptide sequencing led to the discovery of two putative TJ integral proteins that were subsequently named claudin 1 and 2 (Furuse et al. ). So far, 24 members of the claudin family have been identified (Tsukita et al. ). These proteins show sequence similarity to each other and also bear four putative transmembrane domains but do not show any sequence similarity to occludin (Furuse et al. ).

Endothelial cells of the BBB express claudin-1, -3, -5 and -12 (Wolburg and Lippoldt; Krause et al. ). Claudin-5 plays an important role in the maintenance of BBB function. Mice that are claudin-5-deficient are born alive but die within a day after birth with no morphological abnormalities. This can be attributed to the integrity of the BBB of these mice being severely decreased, since it is selectively permeable to molecules with a size of < 800 Da (Nitta et al. ).

The murine claudin-5 promoter has been cloned and characterized (Burek and Förster ). Putative GREs in the promoter sequence have been identified. An increase in claudin-5 promoter activity and mRNA expression occurs after dexamethasone treatment. In addition, increased claudin-5 mRNA and protein expression resulting in higher TER of the endothelial cells has been observed after GC treatment (Fig. 2; Förster et al.; Felinski et al.; Förster; Sadowska et al. ). Claudin-5 is also regulated by estrogens on promoter, mRNA and protein levels (Burek et al. ).

Vascular endothelium cadherin

Together with TJs, adherens junctions (AJs) maintain the restrictiveness of the barrier in endothelial cells (Fig. 2). The most important AJ protein is vascular endothelial cadherin (VE-cadherin), which is exclusively expressed in vessels in which it regulates Ca2+-mediated adhesion (Dejana et al.; Dejana; Gumbiner; Gavard ). Deletion of VE-cadherin in mice produces massive vascular effects leading to early embryonic death. On the other hand, loss of its function provokes a hyperpermeability in adults (Carmeliet et al.; Crosby et al. ).

Treatment of endothelial cells with dexamethasone increases VE-cadherin protein levels. Transcriptional activation of the VE-cadherin promoter by dexamethasone, however, does not point to direct GC-mediated VE-cadherin gene induction (Blecharz et al. ). Although TJs and AJs are formed by different molecules, they are functionally and structurally linked. VE-cadherin at AJs upregulates the gene encoding claudin-5 via the release of the inhibitory activity of the forkhead box factor FoxO1 and the Tcf-4-beta-catenin transcriptional repressor complex (Taddei et al. ).

GC therapeutic strategies and their limitations

The BBB is compromised in many CNS disorders. To function normally, the CNS needs to maintain its microenvironment; this is performed by the BBB via its regulation of molecule transport between the blood and the brain. Since TJ and AJ proteins contribute to endothelial cell barrier restrictiveness, the effects of GCs toward upregulation in the expression of these proteins leading to a tightening of the barrier are used to advantage for therapeutic purposes against many diseases of the CNS including MS, human immunodeficiency (HIV)-1-associated dementia, CNS vasculitides, stroke, Alzheimer’s disease and cerebral malaria (Fig. 3).

Multiple sclerosis

MS, a neuroinflammatory disorder characterized by infiltrating autoreactive T-cells in the CNS, is the most prevalent chronic autoimmune disease in the western world (Noseworthy et al.; Sospedra and Martin ). Most patients suffer from a relapsing-remitting form of the disease whose exacerbations are initiated by BBB breakdown and subsequent tissue damage. Because of the infiltration of activated immune effector cells into the brain, an inflammatory cascade involving leukocytes and humoral components arises (Steinman; Engelhardt ). Even though GC treatment has little effect on the long-term prognosis of MS, high dosage GC therapy is an approved first line treatment for MS relapses (Milligan et al.; Reichhardt ).

For more than 70 years, experimental autoimmune encephalomyelitis (EAE) has served as a model for MS (Gold et al. ). In using this model, together with studies of MS patient, multiple beneficial effects of GC treatment have been established. GCs have anti-inflammatory and immunosuppressive activities and can induce apoptosis. Their induction of apoptosis in T-cells leads to the activation of caspases, release of cathepsin B from lysosomes and increased H2O2 levels (Screpanti et al.; Gold et al. ). GCs inhibit the disruption of the BBB and hence reduce leukocyte infiltration into the CNS (Paul and Bolton ). Direct effects of GCs on the BBB have been demonstrated in vitro (Tischner and Reichardt ). For instance, in cultured brain endothelial cells, dexamethasone induces pore reduction and F-actin concentration on the cell periphery and increases ZO-1 and occludin expression (Romero et al.; Förster et al., ). In addition, the administration of dexamethasone and HC preserves the functional integrity of TJs and AJs under pro-inflammatory conditions by maintaining the levels of TJ components such as occludin, claudin-1, claudin-12, ZO-1 and VE-cadherin. However, dexamethasone effects on claudin-5 are negligible (Förster et al.; Blecharz et al. ).

ICAM-1 and VCAM-1 are expressed by endothelial cells of the BBB in response to pro-inflammatory cytokines such as interferon-γ and TNFα. Treatment with GCs reduces the expression of these adhesion molecules (Gelati et al.; Sloka and Stefanelli ). Accordingly, integrins on encephalitogenic T-cells interact with these adhesion molecules, which are required for the extravasation of additional effector T-cells into the CNS (Engelhardt ). Production of interleukin-8 by monocytes, which also contributes to BBB disruption through leukocyte recruitment to the CNS, is also decreased in MS patients following GC treatment (Mirowska-Guzel et al. ).

The opening of the BBB as promoted by cytokines has been shown to occur because of TJ protein degradation and decreased synthesis. This results in compromised junctional integrity (Harkness et al.; Chang and Werb; Silwedel and Förster; Yang et al. ). TJ degradation in neuroinflammatory conditions such as MS results from the effects of matrix metalloproteinases (MMPs) in BBB disruption. MMP-9 (gelatinase B) is increased in cerebrospinal fluid levels in MS patients. An important regulator of MMP activity is via binding to a family of homologous proteins referred to as tissue inhibitors of MMPs (TIMPs; Brew et al. ). All four known TIMPS have been demonstrated in the BBB endothelium (Hartmann et al. ). In MS patients, TIMP levels are reduced in comparison with controls. This suggests an imbalance in MMP-9/TIMP ratios (Avolio et al. ). GC treatment reduces levels of MMP-9, based on the GC-mediated activation of the TIMP-1 gene and has been shown to lead to an upregulation of TIMP-1 in the murine cerebral vascular endothelial cell line, cEND (Förster et al. ). In contrast, HC has been revealed selectively to upregulate TIMP-3, whereas TIMP-1, TIMP-2 and TIMP-4 are downregulated at the mRNA-level in endothelial cells of cerebral capilllaries in porcine brain. This effect can be completely reversed by the GR inhibitor mifepristone. The application of HC leads to a strong enrichment of TIMP-3 in the endothelial cell membrane (Hartmann et al. ). Moreover, the downregulation of claudin-5 and occludin protein and mRNA levels occurs together with MMP-9 expression upregulation after incubation of the murine microvascular endothelial cells, cEND, with serum from MS patients (Blecharz et al. ).

Ischemic stroke

GCs are known to stabilize the BBB in many inflammatory CNS disorders and even to decrease edema formation. However, in some other cases of CNS disease, it tends to aggravate the condition rather than diminish the negative effects. For instance, when GC treatment is applied to acute ischemic stroke, it is ineffective or even harmful (Saul et al.; Norris and Hachinski; De Reuck et al.; Kumar et al.; Norris; Poungvarin; Roberts et al. ). This is attributed to GC insensitivity at the hypoxic BBB. In the cultured murine brain microvascular endothelial cells, cEND, O2/glucose deprivation reduces TJ protein expression and TER. Treatment with dexamethasone fails to reverse these effects during hypoxia. Apparently, proteasome-dependent degradation of the GR impairs GR transactivation, in turn preventing physiological GC activity. Inhibition of the proteasome with Bortezomib, however, fully restores the BBB stabilizing properties of GC during O2/glucose deprivation (Kleinschnitz et al. ).

Effects of ubiquitination on GC response during hypoxia

Post-translational modifications of the GR include phosphorylation under various conditions by cyclin-dependent kinases and mitogen-activated protein kinases (MAPKs), sumoylation and ubiquitination (Tischner and Reichardt ). Ubiquitination determines protein longevity in cells and plays major roles in signaling (Ernst and Sidhu ) being a form of post-translational modification that targets a protein for rapid degradation by the proteasome (Meller ). Excessive proteosomal GR degradation in response to long-term GC exposure has been shown to lead to GC insensitivity in the vascular endothelium (Förster et al. ). An endothelial GR protein has been identified as a potential proteasome substrate after hypoxia (Kleinschnitz et al. ).

GC responses are dependent on the post-translational modification and degradation of GR to which GC binds to form a complex and begin its activity. The ubiquitin-proteosome system plays a major part in this modification and degradation. Degradation of the proteasome by nuclear receptors is a physiological process necessary to terminate transcriptional activity after ligand binding. It can, however, also restrict transcriptional signaling by steroids under certain pathophysiological conditions thereby compromising steroid function (Meller ). In an in vitro BBB model subjected to O2/glucose deprivation, degradation of the GR in a proteasome-dependent manner leading to impaired GC sensitivity has been observed. When the proteasome is inhibited, the responsivity of the BBB to GC during hypoxia is restored. When proteosomal inhibition is combined with GC treatment, edema formation is attenuated, as are neurological deficits after transient middle cerebral artery occlusion (tMCAO) in mice, which is an established in vivo model of hypoxic BBB damage (Kleinschnitz et al. ).

In addition, studies have shown that cell-death-mediating proteins are rapidly degraded by the ubiquitin-proteosome system. For instance, some pro-apoptotic proteins such as Bim and Puma have been identified as direct GR targets (Erlacher et al.; Wang et al. ). Therefore, a better understanding of the mechanisms by which this occurs might prove to be useful for therapy during ischemia and other brain injuries.

Action of GC-based combination therapy with proteosomal inhibitors against edema

Although GCs diminish edema formation in neuroinflammatory diseases such as acute MS lesions and in certain brain tumors, they are ineffective or even harmful in brain disorders such as acute ischemic stroke or traumatic brain injury (TBI; Kumar et al. ). Stroke and other forms of ischemic brain injury result in excessive edema formation in the brain leading to morbidity and mortality (Kahle et al. ). Therefore, the finding that GCs can diminish edema in some neuroinflammatory diseases but not in ischemia or TBI is unfortunate.

Degradation of GR occurs during O2/glucose deprivation in cEND cells and in the tMCAO model of stroke (Kleinschnitz et al. ). However, the use of pharmacological proteasome inhibitors is able to prevent it. GR transactivation by GC binding has been found to be maintained through the overexpression of a GR mutant resistant to proteasomal degradation (GR-K426A mutant; Wallace and Cidlowski ). These findings have led to the development of a combined treatment strategy by using GCs combined with inhibitors of the proteasome. This novel therapy effectively and significantly reduces edema formation. Furthermore, it significantly ameliorates neurological performance in mouse models of stroke and TBI (Kleinschnitz et al. ).

Concluding remarks

The ability of GCs to improve barrier properties and induce the expression of TJ proteins occludin and claudin-5 and AJ protein VE-cadherin demonstrates their positive effects toward the BBB. Even though high dosage administration of GCs has been found to be ineffective or even harmful in brain disorders such stroke or TBI, novel strategies such as combination therapy of GCs and proteasome inhibitors have proven effective in the prevention of BBB disruption, edema formation and neuronal damage upon brain injury both in vivo and in vitro. Therefore, further studies concerning the GR-mediated regulation of BBB permeability are needed for the development of more and better therapeutic strategies with GCs.

Currently, the establishment of an in vitro human stroke model based on human brain capillary endothelial cells in our working group together with cooperating partners is underway. The model is in the process of being tested, verified and strengthened for use in various experimental procedures. Once this model is established, it should prove highly beneficial in medical and biological research.

References 101

  1. 1.

    Anko-Akatsuka Y, Saitou M, Hirase T, Kishi M, Sakakibara A, Itoh M, Yonemura S, Furuse M, Tsukita S. Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues. J Cell Biol. 1996;133:43-47.

    Not in our library10.1083/jcb.133.1.43

  2. 2.

    Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzili C, Stecchi S, Giaquinto P, Livrea P, Trojano M. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler. 2005;11:441-446.

    Not in our library10.1191/1352458505ms1193oa

  3. 3.

    Balda MS, Whitney J, Flores C, Gonzalez S, Cereijido M, Malter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol. 1996;134:1031-1049.

    Not in our library10.1083/jcb.134.4.1031

  4. 4.

    Ballabh P, Braun A, Nedergaard M. The blood brain barrier: an overview. Structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1-13.

    Not in our library10.1016/j.nbd.2003.12.016

  5. 5.

    Bamforth SD, Kniesel U, Wolburg H, Engelhardt B, Risau W. A dominant mutant of occludin disrupts tight junction structure and function. J Cell Sci. 1999;112:1879-1888.

    Not in our library10.1242/jcs.112.12.1879

  6. 6.

    Beato M. Gene regulation by steroid hormones. Cell. 1989;56:335-344.

    Not in our library10.1016/0092-8674(89)90237-7

  7. 7.

    Blecharz KG, Drenckhahn D, Förster CY. Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells. J Cereb Blood Flow Metab. 2008;28:1139-1149.

    Not in our library10.1038/jcbfm.2008.2

  8. 8.

    Blecharz KG, Haghikia A, Stasiolek M, Kruse N, Drenckhahn D, Gold R, Roewer N, Chan A, Förster CY. Glucocorticoid effects on endothelial barrier function in the murine barin endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult Scler. 2010;16:293-302.

    Not in our library10.1177/1352458509358189

  9. 9.

    Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta. 2000;1477:267-283.

    Not in our library10.1016/s0167-4838(99)00279-4

  10. 10.

    Burek M, Förster CY. Cloning and characterization of the murine claudin-5 promoter. Mol Cell Endocrinol. 2009;298:19-24.

    Not in our library10.1016/j.mce.2008.09.041

  11. 11.

    Burek M, Arias-Loza PA, Roewer N, Förster C. Claudin-5 as a novel estrogen target in vascular endothelium. Arterioscler Thromb Vasc Biol. 2010;30:298-304.

    Not in our library10.1161/atvbaha.109.197582

  12. 12.

    Buse P, Woo PL, Alexander DB, Reza A, Firestone GL. Glucocorticoid-induced functional polarity of growth factor responsiveness regulates tight junction dynamics in transformed mammary epithelial tumor cells. J Biol Chem. 1995;270:28223-28227.

    Not in our library10.1074/jbc.270.47.28223

  13. 13.

    Calabria AR, Weidenfeller C, Jones AR, de Vries HE, Shusta EV. Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. J Neurochem. 2006;97:922-933.

    Not in our library10.1111/j.1471-4159.2006.03793.x

  14. 14.

    Carmeliet P, Lampugnani M, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oosthuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A, Poelmann R, Lupu F, Herbert JM, Collen D, Dejana E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999;98:147-157.

    Not in our library10.1016/s0092-8674(00)81010-7

  15. 15.

    Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11:S37-S43.

    Not in our library10.1016/s0962-8924(01)02122-5

  16. 16.

    Citi S. The molecular organization of tight junctions. J Cell Biol. 1993;121:485-489.

    Not in our library10.1083/jcb.121.3.485

  17. 17.

    Crosby CV, Fleming P, Argraves WS, Corada M, Zanetta L, Dejana E, Drake CJ. VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood. 2005;105:2771-2776.

    Not in our library10.1182/blood-2004-06-2244

  18. 18.

    Dao-Phan HP, Formstecher P, Lefebvre P. Disruption of the glucocorticoid receptor assembly with heat shock protein 90 by a peptidic antiglucocorticoid. Mol Endocrinol. 1997;11:962-972.

    Not in our library10.1210/mend.11.7.9937

  19. 19.

    De Reuck J, Vandekerckhove T, Bosma G, De Meulemeester K, Van Landegem W, De Waele J, Tack E, De Koninck J. Steroid treatment in acute ischaemic stroke. A comparative retrospective study of 556 cases. Eur Neurol. 1988;28:70-72.

    Not in our library10.1159/000116232

  20. 20.

    Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004;5:261-270.

    Not in our library10.1038/nrm1357

  21. 21.

    Dejana E, Bazzoni G, Lampugnani MG. Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp Cell Res. 1999;252:13-19.

    Not in our library10.1006/excr.1999.4601

  22. 22.

    Dittmar KD, Demady D, Stancato LF, Krishna P, Pratt WB. Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The role of p23 is to stabilize receptor.hsp90 heterocomplexes formed by hsp90.p60.hsp70. J Biol Chem. 1997;272:21213-21220.

    Not in our library10.1074/jbc.272.34.21213

  23. 23.

    Drouin J, Lu Y, Nemer M. Glucocorticoid repression of pro-opiomelanocortin gene transcription. J Steroid Biochem. 1989;34:63-69.

    Not in our library10.1016/0022-4731(89)90066-6

  24. 24.

    Engelhardt B. Molecular mechanisms involved in T cell migration across the blood–brain barrier. J Neural Transm. 2006;113:477-485.

    Not in our library10.1007/s00702-005-0409-y

  25. 25.

    Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, Adams JM, Strasser A, Villunger A. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood. 2005;106:4131-4138.

    Not in our library10.1182/blood-2005-04-1595

  26. 26.

    Ernst A, Sidhu S. Engineering ubiquitin to modulate the ubiquitin proteosome system. Cell Cycle. 2013;12:1651-1652.

    Not in our library10.4161/cc.24985

  27. 27.

    Evans R. The steroid and thyroid hormone superfamily. Science. 1988;240:889-895.

    Not in our library10.1126/science.3283939

  28. 28.

    Felinski EA, Cox A, Phillips BE, Antonetti DA. Glucocorticoids induce transactivation of tight junction genes occludin and claudin-5 in retinal endothelial cells via a novel cis-element. Exp Eye Res. 2008;86:867-878.

    Not in our library10.1016/j.exer.2008.01.002

  29. 29.

    Förster C. Tight junctions and the modulation of barrier function ion disease. Histochem Cell Biol. 2008;130:55-70.

    Not in our library10.1007/s00418-008-0424-9

  30. 30.

    Förster C, Silwedel C, Golenhofen N, Burek M, Kietz S, Mankertz J, Drenckhahn D. Occludin as direct target for glucocorticoid-induced improvement of blood–brain barrier properties in a murine in vitro system. J Physiol (Lond). 2005;565:475-486.

    Not in our library10.1113/jphysiol.2005.084038

  31. 31.

    Förster C, Waschke J, Burek M, Leeres J, Drenckhahn D. Glucocorticoid effects on microvascular endothelial barrier permeability are brain specific. J Physiol (Lond). 2006;573:413-425.

    Not in our library10.1113/jphysiol.2006.106385

  32. 32.

    Förster C, Kietz S, Kahles T, Drenckhahn D. Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol (Lond). 2007;580:937-949.

    Not in our library10.1113/jphysiol.2007.129007

  33. 33.

    Förster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. Differential effects of hydrocortisone and TNF alpha on tight junction proteins in an in vitro model of the human blood brain barrier. J Physiol (Lond). 2008;586:1937-1949.

    Not in our library10.1113/jphysiol.2007.146852

  34. 34.

    Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993;123:1777-1788.

    Not in our library10.1083/jcb.123.6.1777

  35. 35.

    Furuse M, Fujimoto K, Sato N, Hirase T, Tsukita S. Overexpression of occludin, a tight-junction associated integral membrane protein, induces the formation of intracellular multi-lamellar bodies bearing tight junction-like structures. J Cell Sci. 1996;109:429-435.

    Not in our library10.1242/jcs.109.2.429

  36. 36.

    Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and −2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998;141:1539-1550.

    Not in our library10.1083/jcb.141.7.1539

  37. 37.

    Gavard J. Breaking the VE-cadherin bonds. FEBS Lett. 2009;583:1-6.

    Not in our library10.1016/j.febslet.2008.11.032

  38. 38.

    Gelati M, Corsini E, Dufour A, Massa G, Giombini S, Solero CL, Salmaggi A. High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium. Can J Neurol Sci. 2000;27:241-244.

    Not in our library10.1017/s0317167100000883

  39. 39.

    Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129:1953-1971.

    Not in our library10.1093/brain/awl075

  40. 40.

    Gonzalez-Mariscal L, Betanzos A, Nava P, Jamarillo BE. Tight junction proteins. Prog Biophys Mol Biol. 2003;81:1-44.

    Not in our library10.1016/s0079-6107(02)00037-8

  41. 41.

    Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6:622-634.

    Not in our library10.1038/nrm1699

  42. 42.

    Harke N, Leers J, Kietz S, Drenckhahn D, Förster C. Identification of a distal glucocorticoid responsive element in the occludin gene coding region. Mol Cell Endocrinol. 2008;295:39-47.

    Not in our library10.1016/j.mce.2008.08.011

  43. 43.

    Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J, Woodroofe MN. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain. 2000;123:698-709.

    Not in our library10.1093/brain/123.4.698

  44. 44.

    Hartmann C, El-Gindi J, Lohmann C, Lischper M, Zeni P, Galla HJ. TIMP-3: a novel target for glucocorticoid signaling at the blood–brain barrier. Biochem Biophys Res Commun. 2009;390:182-186.

    Not in our library10.1016/j.bbrc.2009.08.158

  45. 45.

    Hawle P, Siepmann M, Harst A, Siderius M, Reusch HP, Obermann WM. The middle domain of Hsp90 acts as a discriminator between different types of client protein. Mol Cell Biol. 2006;26:8385-8395.

    Not in our library10.1128/mcb.02188-05

  46. 46.

    Hoheisel D, Nitz T, Franke H, Wegener J, Hakvoort A, Tilling T, Galla HJ. Hydrocortisone reinforces the blood brain barrier properties in a serum-free cell-culture system. Biochem Biophys Res Commun. 1998;244:312-316.

    Not in our library10.1006/bbrc.1997.8051

  47. 47.

    Kahle KT, Simard J, Staley KJ, Nahed BV, Jones PS, Sun D. Molecular mechanisms of ischemic cerebral edema: role of electroneutral ion transport. Physiology (Bethesda). 2009;24:257-265.

    Not in our library10.1152/physiol.00015.2009

  48. 48.

    Kleinschnitz C, Blecharz K, Kahles T, Schwarz T, Kraft P, Thum T, Stoll G, Förster C. Glucocorticoid insensitivity at the hypoxic blood–brain-barrier can be reversed by inhibition of the proteasome. Stroke. 2011;42:1081-1089.

    Not in our library10.1161/strokeaha.110.592238

  49. 49.

    Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE. Structure and function of claudins. Biochim Biophys Acta. 2008;1778:631-645.

    Not in our library10.1016/j.bbamem.2007.10.018

  50. 50.

    Kumar N, Jain S, Maheshwari MC. Role of dexamethasone in the outcome from acute stroke. J Assoc Physicians India. 1989;37:315-317.

    Not in our library

  51. 51.

    Leach L, Lammiman M, Babawale MO, Hobson SA, Bromilou B, Lovat S, Simmonds MJ. Molecular organization of tight and adherens junctions in the human placental vascular tree. Placenta. 2000;21:547-557.

    Not in our library10.1053/plac.2000.0541

  52. 52.

    Lewis-Tuffin LJ, Cidlowski J. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci. 2006;1069:1-9.

    Not in our library10.1196/annals.1351.001

  53. 53.

    Lohmann C, Hüwel S, Galla HJ. Predicting blood brain barrier permeability of drugs: evaluation of different in vitro assays. J Drug Target. 2002;10:263-276.

    Not in our library10.1080/10611860290031903

  54. 54.

    Lu NZ, Cidlowski J. The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci. 2004;1024:102-123.

    Not in our library10.1196/annals.1321.008

  55. 55.

    Madara J. Tight junction dynamics: is paracellular transport regulated? Cell. 1988;53:497-498.

    Not in our library10.1016/0092-8674(88)90562-4

  56. 56.

    Madra JL, Barenberg D, Carlson S. Effects of cytochalasin D on occludin junctions of intestinal absorptive cells: further evidence that the cytoskeleton may influence paracellular permeability and junctional charge selectivity. J Cell Biol. 1986;102:2125-2136.

    Not in our library10.1083/jcb.102.6.2125

  57. 57.

    McCarthy KM, Skare I, Stankewich MC, Furuse M, Tsukita S, Rogers RA, Lynch RD, Schneeberger EE. Occludin is a functional component of the tight junction. J Cell Sci. 1996;109:2287-2298.

    Not in our library10.1242/jcs.109.9.2287

  58. 58.

    Meller R. The role of the ubiqutitin proteosome system in ischemia and ischemic tolerance. Neuroscientist. 2009;15:243-260.

    Not in our library10.1177/1073858408327809

  59. 59.

    Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987;50:511-516.

    Not in our library10.1136/jnnp.50.5.511

  60. 60.

    Mirowska-Guzel DM, Kurowska K, Skierski J, Koronkiewicz M, Wicha W, Kruszewska J, Czlonkowski A, Czlonkowska A. High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. J Neuroimmunol. 2006;176:134-140.

    Not in our library10.1016/j.jneuroim.2006.03.024

  61. 61.

    Nakai Y, Usui T, Tsukada T, Takahashi H, Fukata J, Fukushima M, Senoo K, Imura H. Molecular mechanisms of glucocorticoid inhibition of human pro-opiomelanocortin gene transcription. J Steroid Biochem Mol Biol. 1991;40:301-306.

    Not in our library10.1016/0960-0760(91)90195-b

  62. 62.

    Neuwelt E, Abbott N, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q, Drewes LR. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008;7:84-96.

    Not in our library10.1016/s1474-4422(07)70326-5

  63. 63.

    Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S. Size-selective loosening of the blood brain barrier in claudin-5 deficient mice. J Cell Biol. 2003;161:653-660.

    Not in our library10.1083/jcb.200302070

  64. 64.

    Norris J. Steroids may have a role in stroke therapy. Stroke. 2004;35:228-229.

    Not in our library10.1161/01.str.0000105930.29558.db

  65. 65.

    Norris JW, Hachinski V. High dose steroid treatment in cerebral infarction. BMJ. 1986;292:21-23.

    Not in our library10.1136/bmj.292.6512.21

  66. 66.

    Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938-952.

    Not in our library10.1056/nejm200009283431307

  67. 67.

    Paul C, Bolton C. Inhibition of blood–brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A. Int J Immunopharmacol. 1995;17:497-503.

    Not in our library10.1016/0192-0561(95)00034-y

  68. 68.

    Picard D, Salser S, Yamamoto KR. A movable and regulable inactivation function within the steroid binding domain of the glucocorticoid receptor. Cell. 1988;54:1073-1080.

    Not in our library10.1016/0092-8674(88)90122-5

  69. 69.

    Poungvarin N. Steroids have no role in stroke therapy. Stroke. 2004;35:229-230.

    Not in our library10.1161/01.str.0000105931.81723.26

  70. 70.

    Pujols L, Mullol J, Pérez M, Roca-Ferrer J, Juan M, Xaubet A, Cidlowski JA, Picado C. Expression of human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol. 2001;24:49-57.

    Not in our library10.1165/ajrcmb.24.1.4024

  71. 71.

    Reichhardt H. Immunomodulatory activities of glucocorticoids: insights from transgenesis and gene targeting. Curr Pharm Des. 2004;10:2797-2805.

    Not in our library10.2174/1381612043383575

  72. 72.

    Rhen T, Cidlowski J. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353:1711-1723.

    Not in our library10.1056/nejmra050541

  73. 73.

    Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, Laloe V, Munoz-Sanchez A, Arango M, Hartzenberg B, Khamis H, Yutthakasemsunt S, Komolafe E, Olldashi F, Yadav Y, Murillo-Cabezas F, Shakur H, Edwards P. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004;364:1321-1328.

    Not in our library10.1016/s0140-6736(04)17188-2

  74. 74.

    Romero IA, Radewicz K, Jubin E, Michel CC, Greenwood J, Couraud PO, Adamson P. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett. 2003;344:112-116.

    Not in our library10.1016/s0304-3940(03)00348-3

  75. 75.

    Sadowska GB, Malaeb S, Stonestreet BS. Maternal glucocorticoid exposure alters tight junction protein expression in the brain of fetal sheep. Am J Physiol Heart Circ Physiol. 2010;298:H179-H188.

    Not in our library10.1152/ajpheart.00828.2009

  76. 76.

    Saitou M, Fujimoto K, Doi Y, Itoh M, Fujimoto T, Furuse M, Takano H, Noda T, Tsukita S. Occludin-deficient embryonic stem cells can differentiate into polarized epithelial cells bearing tight junctions. J Cell Biol. 1998;141:397-408.

    Not in our library10.1083/jcb.141.2.397

  77. 77.
    Complex Phenotype of Mice Lacking Occludin, a Component of Tight Junction Strands · 2000
    Not checked
  78. 78.

    Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman FM, Yamamoto KR. Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev. 1988;2:1144-1154.

    Not in our library10.1101/gad.2.9.1144

  79. 79.

    Saul TG, Ducker T, Salcman M, Carro E. Steroids in severe head injury: a prospective randomized clinical trial. J Neurosurg. 1981;54:596-600.

    Not in our library10.3171/jns.1981.54.5.0596

  80. 80.

    Schaaf MJM, Cidlowski J. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol. 2003;83:37-48.

    Not in our library10.1016/s0960-0760(02)00263-7

  81. 81.

    Schneeberger EE, Lynch RD. Structure, function and regulation of cellular tight junctions. Am J Physiol. 1992;262:L647-L661.

    Not in our library10.1152/ajplung.1992.262.6.l647

  82. 82.

    Schweingruber N, Reichardt S, Lühder F, Reichardt HM. Mechanisms of glucocorticoids in the control of neuroinflammation. J Neuroendocrinol. 2011;24:174-182.

    Not in our library10.1111/j.1365-2826.2011.02161.x

  83. 83.

    Screpanti I, Morrone S, Meco D, Santoni A, Gulino A, Paolini R, Crisanti A, Mathieson BJ, Frati L. Steroid sensitivity of thymocyte subpopulations during intrathymic differentitation. Effects of 17 beta-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J Immunol. 1989;142:3378-3383.

    Not in our library

  84. 84.

    Silwedel C, Förster C. Differential susceptibility of cerebral and cerebellar murine brain microvascular endothelial cells to loss of barrier properties in response to inflammatory stimuli. J Neuroimmunol. 2006;179:37-45.

    Not in our library10.1016/j.jneuroim.2006.06.019

  85. 85.

    Singer KL, Stevenson B, Woo PL, Firestone GL. Relationship of serine/threonine phosphorylation/dephosphorylation signaling to glucocorticoid regulation of tight junction permeability and ZO-1 distribution in non-transformed mammary epithelial cells. J Biol Chem. 1994;269:16108-16115.

    Not in our library

  86. 86.

    Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005;11:425-432.

    Not in our library10.1191/1352458505ms1190oa

  87. 87.

    Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747.

    Not in our library10.1146/annurev.immunol.23.021704.115707

  88. 88.

    Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2:762-764.

    Not in our library10.1038/ni0901-762

  89. 89.

    Subramaniam N, Cairns W, Okret S. Glucocorticoids repress transcription from a negative glucocorticoid response element recognized by two homeodomain-containing proteins, Pbx and Oct-1. J Biol Chem. 1998;273:23567-23574.

    Not in our library10.1074/jbc.273.36.23567

  90. 90.

    Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, Potente M, Daly C, Dimmeler S, Dejana E. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol. 2008;10:923-934.

    Not in our library10.1038/ncb1752

  91. 91.

    Tischner D, Reichardt H. Glucocorticoids in the control of neuroinflammation. Mol Cell Endocrinol. 2007;275:62-70.

    Not in our library10.1016/j.mce.2007.03.007

  92. 92.

    Tsai MJ, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1995;63:451-486.

    Not in our library10.1146/annurev.bi.63.070194.002315

  93. 93.

    Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285-293.

    Not in our library10.1038/35067088

  94. 94.

    Umland SP, Schleimer R, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Therap. 2002;15:35-50.

    Not in our library10.1006/pupt.2001.0312

  95. 95.

    Wallace AD, Cidlowski J. Proteosome-mediated glucocorticoid receptor degradation resticts transcriptional signaling by glucocorticoids. J Biol Chem. 2001;276:42714-42721.

    Not in our library10.1074/jbc.m106033200

  96. 96.

    Wang D, Müller N, McPherson KG, Reichardt HM. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J Immunol. 2006;176:1695-1702.

    Not in our library10.4049/jimmunol.176.3.1695

  97. 97.

    Weidenfeller C, Schrot S, Zozulya A, Galla HJ. Murine brain capillary endothelial cells exhibit improved barrier properties under the influence of hydrocortisone. Brain Res. 2005;1053:162-174.

    Not in our library10.1016/j.brainres.2005.06.049

  98. 98.

    Weksler BB, Subileau E, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greewnrood J, Romero IA, Couraud PO. Blood brain barrier specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872-1874.

    Not in our library10.1096/fj.04-3458fje

  99. 99.

    Wikstrom AC, Okret S, Bakke O, Fuxe K, Gustafsson JA. Glucocorticoid mechanism of action: monoclonal antibodies as experimental tools. Med Oncol Tumor Pharmacother. 1986;3:185-196.

    Not in our library10.1007/bf02934995

  100. 100.

    Wolburg H, Lippoldt A. Tight junctions of the blood brain barrier: development, composition and regulation. Vasc Pharmacol. 2002;2002:323-337.

    Not in our library10.1016/s1537-1891(02)00200-8

  101. 101.

    Yang Y, Estrada E, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab. 2007;27:697-709.

    Not in our library10.1038/sj.jcbfm.9600375

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.